Posttreatment recurrence of malignant brain neoplasm: Accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction

Radiology

Volumn 250, Issue 3, 2009, Pages 887-896

  Gasparetto, Emerson L ^a,b   Pawlak, Mikolaj A ^a,c   Patel, Sohil H ^a   Huse, Jason ^d   Woo, John H ^a   Krejza, Jaroslaw ^a,e   Rosenfeld, Myrna R ^a   O'Rourke, Donald M ^a   Lustig, Robert ^a   Melhem, Elias R ^a   Wolf, Ronald L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CISPLATIN; GADODIAMIDE; IRINOTECAN; LOMUSTINE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; BRAIN CANCER; BRAIN NECROSIS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL FEATURE; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HISTOPATHOLOGY; HUMAN; IMAGE ENHANCEMENT; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TREATMENT RELATED NECROSIS;

ADULT; AGED; BLOOD VOLUME; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 62649103363     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2502071444     Document Type: Article

References (50)

1. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis ofthe brain aftertreatment. Radiology 2000;217:377-384.
2. Mullins ME, Barest GD, Schaefer PW, Hochberg FH, Gonzalez RG, Lev MH. Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR Am J Neuroradiol 2005;26:1967-1972.
3. Rabinov JD, Lee PL, Barker FG, et al. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 2002;225:871-879.
4. Weybright P, Sundgren PC, Maly P, et al. Differentiation between brain tumor recurrence and radiation injury using MR spec-troscopy. AJR Am J Roentgenol 2005;185:1471-1476.
5. Asao C, Korogi Y, Kitajima M, et al. Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 2005;26:1455-1460.
6. Hein PA, Eskey CJ, Dunn JF, Hug EB. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004;25:201-209.
7. Hustinx R, Pourdehnad M, Kaschten B, Alavi A. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am 2005;43:35-47.
8. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000;41:1861-1867.
9. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of416 patients with gli-oblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-198.
10. Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21:901-909.
11. Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S. Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum Pathol 2006;37:272-282.
12. Forsyth PA, Kelly PJ, Cascino TL, et al. Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful? J Neurosurg 1995;82:436-444.
13. McGirt MJ, Bulsara KR, Cummings TJ, et al. Prognostic value of magnetic resonance im-aging-guided stereotactic biopsy in the evaluation of recurrent malignant astrocytoma compared with a lesion due to radiation effect. J Neurosurg 2003;98:14-20.
14. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41-51.
15. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values ofperfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989-1998.
16. Rock JP, Scarpace L, Hearshen D, et al. Asso-ciations among magnetic resonance spectros-copy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 2004;54:1111-1117.
17. Rorden C, Brett M. Stereotaxic display of brain lesions. Behav Neurol 2000;12:191-200.
18. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(suppl 1):S208-S219.
19. Kairisto V, Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests: GraphROC for Windows. Scand J Clin Lab Invest Suppl 1995;222:43-60.
20. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-123.
21. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus te-mozolomide followed by adjuvant temozolo-mide. J Clin Oncol 2002;20:1375-1382.
22. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
23. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007;82:81-83.
24. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11-29.
25. Mikkelsen T. Adult neoplasia: overview. In: Gillard JH, Waldman AD, Barker PB, eds. Clinical MR neuroimaging. Cambridge, England: Cambridge University Press, 2005; 279-287.
26. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with ste-reotactic radiosurgery. Int J Cancer 2001;96:191-197.
27. Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 2002;12:615-626.
28. Jacobs AH, Kracht LW, Gossmann A, et al. Imaging in neurooncology. NeuroRx 2005;2:333-347.
29. Lin A, Bluml S, Mamelak AN. Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors. J Neu-rooncol 1999;45:69-81.
30. Preul MC, Leblanc R, Caramanos Z, Kasrai R, Narayanan S, Arnold DL. Magnetic resonance spectroscopy guided brain tumor resection: differentiation between recurrent glioma and radiation change in two diagnos-tically difficult cases. Can J Neurol Sci 1998; 25:13-22.
31. Taylor JS, Langston JW, Reddick WE, et al. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 1996;36:1251-1261.
32. Wald LL, Nelson SJ, Day MR, et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997;87:525-534.
33. Henry RG, Vigneron DB, Fischbein NJ, et al. Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neurora-diol 2000;21:357-366.
34. Biousse V, Newman NJ, Hunter SB, Hudgins PA. Diffusion weighted imaging in radiation necrosis. J Neurol Neurosurg Psychiatry 2003;74:382-384.
35. Covarrubias DJ, Rosen BR, Lev MH. Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 2004;9:528-537.
36. Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist 2003;9:180-188.
37. Hazle JD, Jackson EF, Schomer DF, Leeds NE. Dynamic imaging of intracranial lesions using fast spin-echo imaging: differentiation of brain tumors and treatment effects. J Magn Reson Imaging 1997;7:1084-1093.
38. Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 2004;100:41-46.
39. Lederman G, Wronski M, Arbit E, et al. Treatment of recurrent glioblastoma multi-forme using fractionated stereotactic radio-surgery and concurrent paclitaxel. Am J Clin Oncol 2000;23:155-159.
40. Aronen HJ, Pardo FS, Kennedy DN, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000;6:2189-2200.
41. Aronen HJ, Perkio J. Dynamic susceptibility contrast MRI of gliomas. Neuroimaging Clin N Am 2002;12:501-523.
42. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect ofelevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25:214-221.
43. Speck O, Chang L, DeSilva NM, Ernst T. Perfusion MRI of the human brain with dy-namic susceptibility contrast: gradient-echoversus spin-echo techniques. J Magn Reson Imaging 2000;12:381-387.
44. Donahue KM, Krouwer HG, Rand SD, et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000;43:845-853.
45. Schmainda KM, Rand SD, Joseph AM, et al. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am J Neuroradiol 2004;25:1524-1532.
46. Sugahara T, Korogi Y, Kochi M, Ushio Y, Takahashi M. Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. AJNR Am J Neuroradiol 2001;22:1306-1315.
47. Kanal E, Broome DR, Martin DR, Thomsen HS. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. Radiology 2008;246:11-14.
48. Whitmore RG, Krejza J, Kapoor GS, et al. Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 2007; 107:600- 609.
49. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859-867.
50. Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ 1994;309:102.